HRP20240949T1 - Hibridni interferoni za liječenje virusnih infekcija - Google Patents
Hibridni interferoni za liječenje virusnih infekcija Download PDFInfo
- Publication number
- HRP20240949T1 HRP20240949T1 HRP20240949TT HRP20240949T HRP20240949T1 HR P20240949 T1 HRP20240949 T1 HR P20240949T1 HR P20240949T T HRP20240949T T HR P20240949TT HR P20240949 T HRP20240949 T HR P20240949T HR P20240949 T1 HRP20240949 T1 HR P20240949T1
- Authority
- HR
- Croatia
- Prior art keywords
- subtype
- coronavirus
- hybrid
- interferon
- prophylaxis
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title claims 5
- 230000009385 viral infection Effects 0.000 title claims 5
- 102000014150 Interferons Human genes 0.000 title claims 2
- 108010050904 Interferons Proteins 0.000 title claims 2
- 229940047124 interferons Drugs 0.000 title 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 8
- 108010047761 Interferon-alpha Proteins 0.000 claims 8
- 238000011321 prophylaxis Methods 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 229950000038 interferon alfa Drugs 0.000 claims 3
- 241001678559 COVID-19 virus Species 0.000 claims 2
- 208000001528 Coronaviridae Infections Diseases 0.000 claims 2
- 241000315672 SARS coronavirus Species 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000000840 anti-viral effect Effects 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 208000025721 COVID-19 Diseases 0.000 claims 1
- 241000711573 Coronaviridae Species 0.000 claims 1
- 241001109669 Human coronavirus HKU1 Species 0.000 claims 1
- 241000482741 Human coronavirus NL63 Species 0.000 claims 1
- -1 LAM-002A Chemical compound 0.000 claims 1
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 claims 1
- 229950008454 favipiravir Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (7)
1. Interferon alfa podtip, naznačen time što je interferon alfa podtip HIBRID 2 ili funkcionalno aktivni fragment SEQ ID NO: 3 za uporabu u liječenju i/ili profilaksi virusne infekcije; pri čemu je virusna infekcija infekcija koronavirusom i pri čemu HYBRID 2 sadrži ili se sastoji od aminokiselinske sekvence SEQ ID NO: 3
[image]
2. Interferon alfa podtip za uporabu u liječenju i/ili profilaksi virusne infekcije prema zahtjevu 1, naznačen time što je koronavirus teški akutni respiratorni sindrom koronavirus-1 (SARS-CoV-1), ljudski koronavirus NL63, ljudski koronavirus HKU1, bliskoistočni respiratorni sindrom koronavirus (MERS-CoV) ili teški akutni respiratorni sindrom koronavirus-2 (SARS-CoV-2 ili Covid19).
3. Interferon alfa podtip za uporabu u liječenju i/ili profilaksi virusne infekcije prema bilo kojem od zahtjeva 1 do 2, naznačen time što se interferon alfa podtip primjenjuje sublingvalnom, oralnom ili primjenom injekcije.
4. Interferon podtip prema zahtjevu 3, naznačen time što se interferon alfa podtip primjenjuje u niskoj dozi između 104 do 5x106 IU dnevno.
5. Pripravak koji sadrži interferon alfa podtip, pri čemu je interferon alfa podtip HYBRID 2 ili funkcionalno aktivni fragment SEQ ID NO:3, za uporabu u liječenju i/ili profilaksi infekcije koronavirusom pri čemu HYBRID 2 sadrži ili se sastoji od aminokiselinske sekvence SEQ ID NO: 3
[image]
6. Pripravak prema zahtjevu 5, naznačen time što nadalje sadrži antivirusni spoj.
7. Pripravak prema zahtjevu 6, naznačen time što je antivirusni spoj Remdesivir, LAM-002A, deksametazon ili Avigan.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2003812.1A GB202003812D0 (en) | 2020-03-16 | 2020-03-16 | Compositions and methods relating to the treatment of diseases |
US202063030074P | 2020-05-26 | 2020-05-26 | |
GBGB2012967.2A GB202012967D0 (en) | 2020-08-19 | 2020-08-19 | Compostions and methods relating to the treatment of diseases |
US202063067930P | 2020-08-20 | 2020-08-20 | |
GBGB2102261.1A GB202102261D0 (en) | 2021-02-17 | 2021-02-17 | Compositions and methods relating to the treatment of diseases |
EP21711947.8A EP4121092B1 (en) | 2020-03-16 | 2021-03-16 | Hybrid interferons for treating viral infections |
PCT/GB2021/050649 WO2021186162A1 (en) | 2020-03-16 | 2021-03-16 | Hybrid interferons for treating viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20240949T1 true HRP20240949T1 (hr) | 2024-10-25 |
Family
ID=77770690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20240949TT HRP20240949T1 (hr) | 2020-03-16 | 2021-03-16 | Hibridni interferoni za liječenje virusnih infekcija |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230203120A1 (hr) |
EP (1) | EP4121092B1 (hr) |
JP (1) | JP2023517525A (hr) |
KR (1) | KR20230020943A (hr) |
CN (1) | CN115697377A (hr) |
AU (1) | AU2021238925A1 (hr) |
CA (1) | CA3170629A1 (hr) |
ES (1) | ES2982915T3 (hr) |
HR (1) | HRP20240949T1 (hr) |
HU (1) | HUE067223T2 (hr) |
PL (1) | PL4121092T3 (hr) |
WO (1) | WO2021186162A1 (hr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB202102261D0 (en) * | 2021-02-17 | 2021-03-31 | Ilc Therapeutics Ltd | Compositions and methods relating to the treatment of diseases |
CN113440603B (zh) * | 2020-03-26 | 2022-07-08 | 复旦大学 | 人α干扰素亚型及受体结合相关位点突变体在制备防治新型冠状病毒感染药物中的用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006111745A2 (en) * | 2005-04-20 | 2006-10-26 | Viragen Incorporated | Composition and method for treating viral infection |
GB201215873D0 (en) | 2012-09-05 | 2012-10-24 | Alfacyte Ltd | Compositions and methods relating to the treatment of allergy and allergic diseases |
GB201404403D0 (en) | 2014-03-12 | 2014-04-23 | Alfacyte Ltd | Compositions and methods relating to the treatment of diseases |
ES2971046T3 (es) | 2015-09-15 | 2024-06-03 | Ilc Therapeutics Ltd | Composiciones y métodos relacionados con el tratamiento de enfermedades |
-
2021
- 2021-03-16 KR KR1020227034755A patent/KR20230020943A/ko unknown
- 2021-03-16 WO PCT/GB2021/050649 patent/WO2021186162A1/en active Application Filing
- 2021-03-16 CA CA3170629A patent/CA3170629A1/en active Pending
- 2021-03-16 AU AU2021238925A patent/AU2021238925A1/en active Pending
- 2021-03-16 JP JP2022552669A patent/JP2023517525A/ja active Pending
- 2021-03-16 PL PL21711947.8T patent/PL4121092T3/pl unknown
- 2021-03-16 CN CN202180021884.7A patent/CN115697377A/zh active Pending
- 2021-03-16 US US17/906,569 patent/US20230203120A1/en active Pending
- 2021-03-16 ES ES21711947T patent/ES2982915T3/es active Active
- 2021-03-16 HR HRP20240949TT patent/HRP20240949T1/hr unknown
- 2021-03-16 EP EP21711947.8A patent/EP4121092B1/en active Active
- 2021-03-16 HU HUE21711947A patent/HUE067223T2/hu unknown
Also Published As
Publication number | Publication date |
---|---|
US20230203120A1 (en) | 2023-06-29 |
PL4121092T3 (pl) | 2024-08-19 |
HUE067223T2 (hu) | 2024-10-28 |
EP4121092C0 (en) | 2024-04-24 |
ES2982915T3 (es) | 2024-10-18 |
EP4121092A1 (en) | 2023-01-25 |
EP4121092B1 (en) | 2024-04-24 |
WO2021186162A1 (en) | 2021-09-23 |
AU2021238925A1 (en) | 2022-10-27 |
KR20230020943A (ko) | 2023-02-13 |
JP2023517525A (ja) | 2023-04-26 |
CA3170629A1 (en) | 2021-09-23 |
CN115697377A (zh) | 2023-02-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20240949T1 (hr) | Hibridni interferoni za liječenje virusnih infekcija | |
MX2022010659A (es) | Compuestos altamente activos contra la enfermedad por coronavirus de 2019 (covid-19). | |
AR036728A1 (es) | Composiciones farmaceuticas para el tratamiento de la infeccion causada por el virus de la hepatitis con un perfil de administracion de interferon multifasico | |
HRP20171036T1 (hr) | Kombinacija dvaju antiviralnih sredstava za liječenje hepatitisa c | |
AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
ES541103A0 (es) | Procedimiento de obtencion de una composicion para el trata-miento de infecciones virales | |
HRP20211906T1 (hr) | Dalargin za upotrebu u liječenju akutne respiratorne virusne infekcije | |
TW200509961A (en) | Uses of interferons for the treatment of severe acute respiratory syndrome and other viral infections | |
JP2005525784A5 (hr) | ||
DK200300015A (da) | Anvendelse af stammer af Parapoxvirus ovis til fremstilling af antivirale lægemidler og lægemidler mod cancer | |
MX2024001645A (es) | Metodo para el tratamiento de las enfermedades virales veterinarias. | |
MX2022013195A (es) | Uso de proteina surfactante d para tratar infecciones virales. | |
US4828830A (en) | Method and composition for prophylaxis and treatment of viral infections | |
US7846430B2 (en) | Composition and method for treating bovine papilloma virus in equine | |
WO2021225960A3 (en) | Beta thymosin peptides for treating viral infections | |
EA200501569A1 (ru) | Лечение или профилактика респираторных вирусных инфекций с использованием пептидов альфа-тимозина | |
JP2014510126A5 (ja) | Ifnアルファ関連疾病の処置方法 | |
MX2023007603A (es) | Peptidos para el tratamiento de infecciones respiratorias de origen viral. | |
CA3242034A1 (en) | Pharmaceutical composition for treatment of viral infections | |
NZ587372A (en) | Treatment of bacterial, protozoan infections and cancer with a mixture of at least three different human interferon alpha proteins | |
ES2052579T3 (es) | Empleo de interferon alfa humano recombinante para la fabricacion de un medicamento para tratar el virus del sida. | |
WO2020139163A3 (ru) | Комбинация противовирусных средств | |
SUN et al. | Efficacy of aerosolized recombinant interferons against vesicular stomatitis virus-induced lung infection in cotton rats | |
BR112022006913A2 (pt) | Métodos para tratar infecções virais de hepatite delta | |
Mohammadabadi et al. | Milk Lactoferrin: A Nutraceutical Supplement Against Viruses |